Related references
Note: Only part of the references are listed.Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Basophil count is a sensitive marker for clinical progression in a chronic spontaneous urticaria patient treated with omalizumab
Izumi Kishimoto et al.
ALLERGOLOGY INTERNATIONAL (2019)
Conjunctivitis in dupilumab clinical trials
B. Akinlade et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Successful control of severe eosinophilic granulomatosis with polyangiitis in a pregnancy and perinatal period: A use of mepolizumab
Akira Kasuya et al.
JOURNAL OF DERMATOLOGY (2019)
A case of chronic eosinophilic pneumonia in a patient treated with dupilumab
Francesco Menzella et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2019)
Biological treatments for severe asthma
Sara M. Assaf et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
William W. Busse et al.
LANCET RESPIRATORY MEDICINE (2019)
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)
K. L. Winthrop et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Basophil Fc epsilon RI expression is linked to time to omalizumab response in chronic spontaneous urticaria
Gustavo Deza et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Dupilumab: A New Paradigm for the Treatment of Allergic Diseases
J. Sastre et al.
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2018)
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Klaus F. Rabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
M. Castro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Keith Cooper et al.
PHARMACOECONOMICS (2018)
Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan
Mitsuru Adachi et al.
RESPIRATORY MEDICINE (2018)
Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma
Garry M. Walsh
EXPERT REVIEW OF RESPIRATORY MEDICINE (2018)
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma
Diego Bagnasco et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Implications of Changes in US Food and Drug Administration Prescribing Information Regarding the Safety and Use of Asthma Biologics during Pregnancy
Michael Schatz et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2018)
Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials
Susan J. Tofte et al.
JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS (2018)
Evaluation of inflammatory markers interleukin-6 (IL-6) and matrix metalloproteinase-9 (MMP-9) in asthma
Srilata Puru Naik et al.
JOURNAL OF ASTHMA (2017)
The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis
Jinfeng Li et al.
JOURNAL OF ASTHMA (2017)
The safety of mepolizumab for the treatment of asthma
E. Leung et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials
Carlos Iribarren et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma
Carlos Iribarren et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Omalizumab as Third-Line Therapy for Urticaria During Pregnancy
L. F. Ensina et al.
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2017)
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt et al.
LANCET (2017)
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils
Guy Brusselle et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2017)
Long-term real-life safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study
Danilo Di Bona et al.
RESPIRATORY MEDICINE (2017)
Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
Terufumi Shimoda et al.
ALLERGOLOGY INTERNATIONAL (2017)
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Geoffrey L. Chupp et al.
LANCET RESPIRATORY MEDICINE (2017)
Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects
Jorge Maspero
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2017)
Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma
Kevin Murphy et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2017)
Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma
Ann Esquivel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies
Mitchell Goldman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Evaluation of IgE Antibodies to Omalizumab (Xolair (R)) and Their Potential Correlation to Anaphylaxis
Dana L. Baker et al.
AAPS JOURNAL (2016)
Immunoglobulin E, what is it good for?
Brian T. Kelly et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2016)
Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist
David A. Khan
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2016)
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma Effects Across a Broad Range of Eosinophil Counts
Jonathan Corren et al.
CHEST (2016)
Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study
Njira Lugogo et al.
CLINICAL THERAPEUTICS (2016)
Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study
Phillip L. Lieberman et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Role of biologics in severe eosinophilic asthma - focus on reslizumab
Girolamo Pelaia et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
RESLIZUMAB: MAINTENANCE TREATMENT FOR EOSINOPHILIC ASTHMA INADEQUATELY CONTROLLED ON CORTICOSTEROIDS
D. M. Paton
DRUGS OF TODAY (2016)
The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy
Jennifer Namazy et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial
Christopher E. Brightling et al.
LANCET RESPIRATORY MEDICINE (2015)
Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma
Hui Fang Lim et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2015)
Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis
Tianwen Lai et al.
SCIENTIFIC REPORTS (2015)
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab
Aidan Long et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2014)
Mepolizumab treatment for asthma
Douglas S. Robinson
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes
Florence E. Roufosse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Sally Wenzel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Omalizumab and the risk of malignancy: Results from a pooled analysis
William Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting
Ayad K. Ali et al.
JOURNAL OF ASTHMA AND ALLERGY (2012)
Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma A Systematic Review
Gustavo J. Rodrigo et al.
CHEST (2011)
Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis
Philippe Gevaert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
Sophia Kim et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia
Sabina A. Antoniu
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment
P. J. Cooper et al.
ALLERGY (2008)
Treatment of patients with the hypereosinophilic syndrome with mepolizumab
Marc E. Rothenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma
Patrick Flood-Page et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Omalizumab for asthma
RC Strunk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Represcription of penicillin after allergic-like events
AJ Apter et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma
R Djukanovic et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
W Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys
TK Hart et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
Advances in immunology - Asthma
WW Busse et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
